1443 GMT - Novo Nordisk could benefit from higher volumes as the obesity market evolves, but it will likely take time for investors to give credit, Goldman Sachs analysts write. Pricing across the obesity portfolio will be a headwind, but volumes may offer a partial offset, as well as the launch of oral Wegovy, they say. Expectations have reset sharply downwards, but Goldman Sachs still sees opportunities for Wegovy, CagriSema and oral Wegovy to drive value in excess of what the market currently believes. The bank adjusts estimates to reflect recent newsflow. It cuts its 2026 revenue and EBIT estimates by around 5% and 8%, respectively, and reduces its 2027-2030 revenue and EBIT estimates by 4% to 5%. It lowers its target price on the stock to 353 Danish kroner from 391 kroner and keeps at buy. Shares trade 3.8% higher at 311.30 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 26, 2025 09:46 ET (14:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.